Insider Holders & Insider Ownership - BeiGene Ltd. (BGNE)

List of insiders holdings for BeiGene Ltd.:
  1. Shares directly owned by the insider.
  2. Shares indirectly owned by the insider.
  3. Total shares owned by the insider (sum of shares directly and indirectly owned).
  4. Total market value if available.
  5. Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Insider Holder NameReport
Date Time
Shares Owned
Directly
Indirectly
Total
Shares Owned
Filing
HHLR ADVISORS LTD.
HILLHOUSE INVESTMENT MANAGEMENT LTD.
10% Owner
2023-06-15 19:25:010
142,888,241
142,888,241Form 4
BAKER BROS. ADVISORS LP
14159 L.P.
Baker Bros. Advisors (GP) LLC
BAKER JULIAN
BAKER FELIX
667 L.P.
Baker Brothers Life Sciences LP
Director
10% Owner
2023-11-14 17:18:44138,678,037
0
138,678,037Form 13D
OYLER JOHN
Chief Executive Officer
2024-06-07 16:58:482,735,993
46,190,763
48,926,756Form 4
CB Biotech Investment Ltd
CPEChina Fund L.P.
CITIC PE Associates L.P.
CITIC PE Funds Ltd
10% Owner
2016-02-09 20:07:3519,601,138
0
19,601,138Form 4
AMGEN INC
10% Owner
2021-09-13 19:27:0718,943,802
0
18,943,802Form 4
Wang Xiaodong
Chair, Scientific Advisory Brd
2024-06-07 16:56:195,979,087
5,186,590
11,165,677Form 4
BAKER BROS. ADVISORS LP
667 L.P.
Baker Bros. Advisors (GP) LLC
Baker Brothers Life Sciences LP
BAKER FELIX
BAKER JULIAN
Director
10% Owner
2024-06-07 16:03:2920,838
10,831,600
10,852,438Form 4
Glazer Donald W.
Director
2024-06-07 16:58:012,752,615
0
2,752,615Form 4
Li Ji
EVP and Gl. Head of Bus. Dev.
2018-03-02 18:41:222,721,000
0
2,721,000Form 4
Wang Lai
Global Head of R&D
2024-06-07 17:03:572,087,215
58,188
2,145,403Form 4
Peterson Amy C.
CMO, Immuno-oncology
2018-12-19 18:34:101,966,402
0
1,966,402Form 4
Wu Xiaobin
President, COO & GM China
2024-06-07 17:04:431,758,600
4000
1,762,600Form 4
Liang Howard
CFO & Chief Strategy Officer
2021-06-30 16:45:491,553,149
0
1,553,149Form 4
Yang Jianxin
Sr. VP, Head of Clinical Dev.
2016-07-15 16:34:25825,000
0
825,000Form 4
Yan Wendy Xiaojun
Sr. VP, Head of Reg. Affairs
2016-07-15 16:30:50825,000
0
825,000Form 4
Wang Julia Aijun
Chief Financial Officer
2024-06-07 16:54:31712,985
0
712,985Form 4
Lee Chan Henry
SVP, General Counsel
2024-06-07 17:03:11454,194
0
454,194Form 4
Huang Jane
CMO, Hematology
2021-12-16 17:50:15371,331
0
371,331Form 4
Tang Ke
Director
2017-04-21 16:42:20199,992
0
199,992Form 4
Yuan RuiRong
Chief Medical Officer
2016-02-09 20:08:35130,000
0
130,000Form 4
Malley Thomas
Director
2023-06-20 19:00:29103,671
0
103,671Form 4
HOOPER ANTHONY C
Director
2024-06-07 17:00:4087,906
0
87,906Form 4
Sanders Corazon (Corsee) D.
Director
2024-06-07 16:55:2880,392
0
80,392Form 4
Dugan Margaret
Director
2024-06-07 17:02:2680,106
0
80,106Form 4
Yi Qingqing
Director
2024-06-07 16:31:1780,106
0
80,106Form 4
Riva Alessandro
Director
2024-06-07 16:57:1980,106
0
80,106Form 4
Ball Titus B.
Principal Accounting Officer
2024-06-07 17:05:2463,245
0
63,245Form 4
BRANDICOURT OLIVIER
Director
2024-06-07 17:01:3850,492
0
50,492Form 4
Chen Timothy Yung-Cheng
Director
2021-06-21 16:42:0825,298
0
25,298Form 4
su Jingshyh S
Director
2021-06-21 16:34:1225,298
0
25,298Form 4
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Research GmbH
10% Owner
2018-02-13 16:29:070
0
0Form 13G
GOLLER MICHAEL
Director
2016-02-02 19:40:270
0
0Form 3
KRISHANA RANJEEV
Director
2016-02-02 19:14:150
0
0Form 3